Free Trial

LENZ Therapeutics Q3 2023 Earnings Report

LENZ Therapeutics logo
$25.64 -0.89 (-3.35%)
As of 04:00 PM Eastern

LENZ Therapeutics EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

LENZ Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

LENZ Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

LENZ Therapeutics Earnings Headlines

LENZ Therapeutics Stock Is Attractive Before PDUFA
Equities Analysts Offer Predictions for LENZ Q1 Earnings
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
What is HC Wainwright's Forecast for LENZ Q2 Earnings?
What is William Blair's Estimate for LENZ FY2026 Earnings?
See More LENZ Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email.

About LENZ Therapeutics

LENZ Therapeutics (NASDAQ:LENZ), a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

View LENZ Therapeutics Profile

More Earnings Resources from MarketBeat